Gαs is dispensable for β-arrestin coupling but dictates GRK selectivity and is predominant for gene expression regulation by β2-adrenergic receptor.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 15 02 2023
revised: 03 09 2023
accepted: 14 09 2023
medline: 27 11 2023
pubmed: 30 9 2023
entrez: 29 9 2023
Statut: ppublish

Résumé

β-arrestins play a key role in G protein-coupled receptor (GPCR) internalization, trafficking, and signaling. Whether β-arrestins act independently of G protein-mediated signaling has not been fully elucidated. Studies using genome-editing approaches revealed that whereas G proteins are essential for mitogen-activated protein kinase activation by GPCRs., β-arrestins play a more prominent role in signal compartmentalization. However, in the absence of G proteins, GPCRs may not activate β-arrestins, thereby limiting the ability to distinguish G protein from β-arrestin-mediated signaling events. We used β2-adrenergic receptor (β2AR) and its β2AR-C tail mutant expressed in human embryonic kidney 293 cells wildtype or CRISPR-Cas9 gene edited for Gα

Identifiants

pubmed: 37774973
pii: S0021-9258(23)02321-9
doi: 10.1016/j.jbc.2023.105293
pmc: PMC10641165
pii:
doi:

Substances chimiques

beta-Arrestin 1 0
beta-Arrestin 2 0
beta-Arrestins 0
Cyclic AMP-Dependent Protein Kinases EC 2.7.11.11
GTP-Binding Proteins EC 3.6.1.-
Mitogen-Activated Protein Kinases EC 2.7.11.24
Receptors, Adrenergic, beta-2 0
GTP-Binding Protein alpha Subunits 0
Protein Isoforms 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105293

Subventions

Organisme : NCI NIH HHS
ID : U54 CA209891
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA273974
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217885
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA274502
Pays : United States
Organisme : NLM NIH HHS
ID : T15 LM011271
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest J. S. G. is consultant for Domain Therapeutics, Pangea Therapeutics, and io9, and founder of Kadima Pharmaceuticals, outside the submitted work. M. B. is the president of Domain Therapeutics Scientific Advisory Board. The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Valeria Burghi (V)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

Justine S Paradis (JS)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

Adam Officer (A)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

Sendi Rafael Adame-Garcia (SR)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

Xingyu Wu (X)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

Edda S F Matthees (ESF)

Institut für Molekulare Zellbiologie, CMB - Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena, Germany.

Benjamin Barsi-Rhyne (B)

Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, USA.

Dana J Ramms (DJ)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

Lauren Clubb (L)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

Monica Acosta (M)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA.

Pablo Tamayo (P)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA.

Michel Bouvier (M)

Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Québec, Canada.

Asuka Inoue (A)

Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi, Japan.

Mark von Zastrow (M)

Department of Psychiatry and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California, USA.

Carsten Hoffmann (C)

Institut für Molekulare Zellbiologie, CMB - Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena, Germany.

J Silvio Gutkind (JS)

Moores Cancer Center, University of California San Diego, La Jolla, California, USA; Department of Pharmacology, University of California San Diego, La Jolla, California, USA. Electronic address: sgutkind@health.ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH